Insilico Clinical Trials Market Size Expected To Surpass Around US$ 5.0 Bn by 2030

According to Vision Research Report Reports, the global insilico clinical trials market size was valued at US$ 2.6 Bn in 2021 and is expected to grow at a CAGR of 7.3% from 2022 to 2030.

Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/39181

Growth Factors

Traditional clinical trials require huge expenditure to conduct research. Moreover, a high number of drugs and medical devices fail in the clinical trial owing to the lack of safety and efficacy, which creates huge losses for the clinical trial sponsors. These factors promote the demand for insilico clinical trials, to understand the behavior of drugs or medical devices in humans. Insilico clinical trials use simulation techniques to understand the efficacy and safety of a drug or medical device.

The growth in R&D spending is likely to have a positive impact on the market growth. The COVID-19 pandemic had resulted in a temporary shutdown of clinical research sites, which promoted the demand for insilico clinical trials for research studies. Disruptions in clinical research due to the COVID-19 outbreak have kindled a new level of interest in using computer simulations to predict clinical trial outcomes.

Report Coverage

Report Scope Details
Market Size US$ 5.0 billion by 2030
Growth Rate CAGR of 7.3% From 2022 to 2030
Largest Market North America
Base Year 2021
Forecast Period 2022 to 2030
Segments Covered Industry, Therapeutic Area, Phase
Regional Scope North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Mentioned Caterpillar; CNH Industrial N.V.; Doosan Corporation; Escorts Limited; Hitachi Construction Machinery Co., Ltd.; Hyundai Construction Equipment Co., Ltd.; J C Bamford Excavators Ltd.; Deere & Company.; Kobelco Construction Machinery Co., Ltd.; Komatsu Ltd.; Liebherr-International AG; Manitou BF; HİDROMEK; Sany Heavy Industry Co., Ltd.; Sumitomo Heavy Industries, Ltd.; Terex Corporation; Volvo AB; Zoomlion Heavy Industry Science; Technology Co., Ltd

By Industry Analysis

The medical devices segment accounted for the highest revenue share of more than 57% in 2021. The simulations for medical devices are considered more accurate as compared to pharmaceuticals, which is the key reason for the majority of insilico trials being performed for medical devices.

pharmaceutical segment is expected to grow at the fastest CAGR over the forecast period owing to the increasing demand for innovative treatment options globally. The concerns regarding the harmful effect of drugs on humans in traditional clinical trials are further contributing to the demand for computer simulation trials for pharmaceuticals.

By Therapeutic Area Analysis

Based on therapeutic areas, the market has been further segmented into oncology, infectious disease, hematology, cardiology, dermatology, neurology, diabetes, and others. The oncology segment accounted for the largest revenue share of 27.0% in 2021.

Traditional clinical trials for cancer are considered expensive and also have high chances of incurring harmful effects on humans. These factors are primarily contributing to the demand for cancer insilico clinical trials

The developments in cancer insilico studies have further promoted segment growth. For instance, in May 2021, GNS Healthcare announced the development of the first in silico patient for prostate cancer. However, the infectious diseases segment is expected to register the fastest CAGR over the forecast period.

By Phase Analysis

Based on phases, the market is divided into phases I, II, III, and IV. The phase II segment accounted for the largest revenue share of more than 44.5% in 2021 and is also expected to register the fastest CAGR during the forecast period. The majority of insilico trials are at phase II, which is the prime reason for the largest share of the segment.

The phase II segment is also expected to record significant growth during the forecast period. The rising demand for biologics and personalized medicines across the globe and increasing awareness among the population to eliminate animal studies are a few of the factors supporting the growth of the phase III segment.

By Regional Analysis

North America accounted for the largest revenue share of more than 44% in 2021 and will expand further at a steady CAGR retaining the leading over the forecast period as a significant number of insilico trials are being conducted in the U.S. In addition, the presence of key companies like GNS Healthcare Inc., Insilico Medicine, Inc., Immunetrics Inc., and others in the region have further contributed to the regional market growth.

The market in Asia Pacific is in its nascent stage. Various companies in this region are adopting the use of insilico trials to reduce the overall cost of clinical studies.

Key Players

  • Certara, Inc.
  • Novadiscovery Sas
  • Insilico Medicine, Inc.
  • Dassault Systemes SE
  • GNS Healthcare Inc.
  • The AnyLogic Company
  • InSilicoTrials
  • Immunetrics Inc.
  • Nuventra Pharma Sciences
  • Abzena Ltd.

Market Segmentation

  • By Industry
    • Medical Devices
    • Pharmaceutical
  • By Therapeutic Area
    • Oncology
    • Infectious Disease
    • Hematology
    • Cardiology
    • Dermatology
    • Neurology
    • Diabetes
    • Others
  • By Phase
    • Phase I
    • Phase II
    • Phase III
    • Phase IV
  • Regional
    • North America
      • U.S.
      • Canada
    • Europe
      • U.K.
      • Germany
      • France
      • Spain
      • Italy
    • Asia Pacific
      • India
      • China
      • Japan
      • Australia
      • South Korea
    • Latin America
      • Brazil
      • Mexico
      • Argentina
      • Colombia
    • Middle East & Africa
      • South Africa
      • Saudi Arabia
      • UAE

Table of Contents

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Insilico Clinical Trials Market, By Industry

7.1.  Insilico Clinical Trials Market, by Industry, 2021-2030

7.1.1.    Medical Devices

7.1.1.1.        Market Revenue and Forecast (2019-2030)

7.1.2.    Pharmaceutical

7.1.2.1.        Market Revenue and Forecast (2019-2030)

Chapter 8.  Global Insilico Clinical Trials Market, By Therapeutic Area

8.1.  Insilico Clinical Trials Market, by Therapeutic Area, 2021-2030

8.1.1.    Oncology

8.1.1.1.        Market Revenue and Forecast (2019-2030)

8.1.2.    Infectious Disease

8.1.2.1.        Market Revenue and Forecast (2019-2030)

8.1.3.    Hematology

8.1.3.1.        Market Revenue and Forecast (2019-2030)

8.1.4.    Cardiology

8.1.4.1.        Market Revenue and Forecast (2019-2030)

8.1.5.    Dermatology

8.1.5.1.        Market Revenue and Forecast (2019-2030)

8.1.6.    Neurology

8.1.6.1.        Market Revenue and Forecast (2019-2030)

8.1.7.    Diabetes

8.1.7.1.        Market Revenue and Forecast (2019-2030)

Chapter 9.  Global Insilico Clinical Trials Market, By Phase

9.1.  Insilico Clinical Trials Market, by Phase, 2021-2030

9.1.1.    Phase I

9.1.1.1.        Market Revenue and Forecast (2019-2030)

9.1.2.    Phase II

9.1.2.1.        Market Revenue and Forecast (2019-2030)

9.1.3.    Phase III

9.1.3.1.        Market Revenue and Forecast (2019-2030)

9.1.4.    Phase IV

9.1.4.1.        Market Revenue and Forecast (2019-2030)

Chapter 10.      Global Insilico Clinical Trials Market, Regional Estimates and Trend Forecast

10.1.        North America

10.1.1.  Market Revenue and Forecast, by Industry (2019-2030)

10.1.2.  Market Revenue and Forecast, by Therapeutic Area (2019-2030)

10.1.3.  Market Revenue and Forecast, by Phase (2019-2030)

10.1.4.  U.S.

10.1.4.1.      Market Revenue and Forecast, by Industry (2019-2030)

10.1.4.2.      Market Revenue and Forecast, by Therapeutic Area (2019-2030)

10.1.4.3.      Market Revenue and Forecast, by Phase (2019-2030)

10.1.5.  Rest of North America

10.1.5.1.      Market Revenue and Forecast, by Industry (2019-2030)

10.1.5.2.      Market Revenue and Forecast, by Therapeutic Area (2019-2030)

10.1.5.3.      Market Revenue and Forecast, by Phase (2019-2030)

10.2.        Europe

10.2.1.  Market Revenue and Forecast, by Industry (2019-2030)

10.2.2.  Market Revenue and Forecast, by Therapeutic Area (2019-2030)

10.2.3.  Market Revenue and Forecast, by Phase (2019-2030)

10.2.4.  UK

10.2.4.1.      Market Revenue and Forecast, by Industry (2019-2030)

10.2.4.2.      Market Revenue and Forecast, by Therapeutic Area (2019-2030)

10.2.4.3.      Market Revenue and Forecast, by Phase (2019-2030)

10.2.5.  Germany

10.2.5.1.      Market Revenue and Forecast, by Industry (2019-2030)

10.2.5.2.      Market Revenue and Forecast, by Therapeutic Area (2019-2030)

10.2.5.3.      Market Revenue and Forecast, by Phase (2019-2030)

10.2.6.  France

10.2.6.1.      Market Revenue and Forecast, by Industry (2019-2030)

10.2.6.2.      Market Revenue and Forecast, by Therapeutic Area (2019-2030)

10.2.6.3.      Market Revenue and Forecast, by Phase (2019-2030)

10.2.7.  Rest of Europe

10.2.7.1.      Market Revenue and Forecast, by Industry (2019-2030)

10.2.7.2.      Market Revenue and Forecast, by Therapeutic Area (2019-2030)

10.2.7.3.      Market Revenue and Forecast, by Phase (2019-2030)

10.3.        APAC

10.3.1.  Market Revenue and Forecast, by Industry (2019-2030)

10.3.2.  Market Revenue and Forecast, by Therapeutic Area (2019-2030)

10.3.3.  Market Revenue and Forecast, by Phase (2019-2030)

10.3.4.  India

10.3.4.1.      Market Revenue and Forecast, by Industry (2019-2030)

10.3.4.2.      Market Revenue and Forecast, by Therapeutic Area (2019-2030)

10.3.4.3.      Market Revenue and Forecast, by Phase (2019-2030)

10.3.5.  China

10.3.5.1.      Market Revenue and Forecast, by Industry (2019-2030)

10.3.5.2.      Market Revenue and Forecast, by Therapeutic Area (2019-2030)

10.3.5.3.      Market Revenue and Forecast, by Phase (2019-2030)

10.3.6.  Japan

10.3.6.1.      Market Revenue and Forecast, by Industry (2019-2030)

10.3.6.2.      Market Revenue and Forecast, by Therapeutic Area (2019-2030)

10.3.6.3.      Market Revenue and Forecast, by Phase (2019-2030)

10.3.7.  Rest of APAC

10.3.7.1.      Market Revenue and Forecast, by Industry (2019-2030)

10.3.7.2.      Market Revenue and Forecast, by Therapeutic Area (2019-2030)

10.3.7.3.      Market Revenue and Forecast, by Phase (2019-2030)

10.4.        MEA

10.4.1.  Market Revenue and Forecast, by Industry (2019-2030)

10.4.2.  Market Revenue and Forecast, by Therapeutic Area (2019-2030)

10.4.3.  Market Revenue and Forecast, by Phase (2019-2030)

10.4.4.  GCC

10.4.4.1.      Market Revenue and Forecast, by Industry (2019-2030)

10.4.4.2.      Market Revenue and Forecast, by Therapeutic Area (2019-2030)

10.4.4.3.      Market Revenue and Forecast, by Phase (2019-2030)

10.4.5.  North Africa

10.4.5.1.      Market Revenue and Forecast, by Industry (2019-2030)

10.4.5.2.      Market Revenue and Forecast, by Therapeutic Area (2019-2030)

10.4.5.3.      Market Revenue and Forecast, by Phase (2019-2030)

10.4.6.  South Africa

10.4.6.1.      Market Revenue and Forecast, by Industry (2019-2030)

10.4.6.2.      Market Revenue and Forecast, by Therapeutic Area (2019-2030)

10.4.6.3.      Market Revenue and Forecast, by Phase (2019-2030)

10.4.7.  Rest of MEA

10.4.7.1.      Market Revenue and Forecast, by Industry (2019-2030)

10.4.7.2.      Market Revenue and Forecast, by Therapeutic Area (2019-2030)

10.4.7.3.      Market Revenue and Forecast, by Phase (2019-2030)

10.5.        Latin America

10.5.1.  Market Revenue and Forecast, by Industry (2019-2030)

10.5.2.  Market Revenue and Forecast, by Therapeutic Area (2019-2030)

10.5.3.  Market Revenue and Forecast, by Phase (2019-2030)

10.5.4.  Brazil

10.5.4.1.      Market Revenue and Forecast, by Industry (2019-2030)

10.5.4.2.      Market Revenue and Forecast, by Therapeutic Area (2019-2030)

10.5.4.3.      Market Revenue and Forecast, by Phase (2019-2030)

10.5.5.  Rest of LATAM

10.5.5.1.      Market Revenue and Forecast, by Industry (2019-2030)

10.5.5.2.      Market Revenue and Forecast, by Therapeutic Area (2019-2030)

10.5.5.3.      Market Revenue and Forecast, by Phase (2019-2030)

Chapter 11.  Company Profiles

11.1.              Certara, Inc.

11.1.1.  Company Overview

11.1.2.  Product Offerings

11.1.3.  Financial Performance

11.1.4.  Recent Initiatives

11.2.              Novadiscovery Sas

11.2.1.  Company Overview

11.2.2.  Product Offerings

11.2.3.  Financial Performance

11.2.4.  Recent Initiatives

11.3.              Insilico Medicine, Inc.

11.3.1.  Company Overview

11.3.2.  Product Offerings

11.3.3.  Financial Performance

11.3.4.  Recent Initiatives

11.4.              Dassault Systemes SE

11.4.1.  Company Overview

11.4.2.  Product Offerings

11.4.3.  Financial Performance

11.4.4.  Recent Initiatives

11.5.              GNS Healthcare Inc.

11.5.1.  Company Overview

11.5.2.  Product Offerings

11.5.3.  Financial Performance

11.5.4.  Recent Initiatives

11.6.              The AnyLogic Company

11.6.1.  Company Overview

11.6.2.  Product Offerings

11.6.3.  Financial Performance

11.6.4.  Recent Initiatives

11.7.              InSilicoTrials

11.7.1.  Company Overview

11.7.2.  Product Offerings

11.7.3.  Financial Performance

11.7.4.  Recent Initiatives

11.8.              Immunetrics Inc.

11.8.1.  Company Overview

11.8.2.  Product Offerings

11.8.3.  Financial Performance

11.8.4.  Recent Initiatives

11.9.              Nuventra Pharma Sciences

11.9.1.  Company Overview

11.9.2.  Product Offerings

11.9.3.  Financial Performance

11.9.4.  Recent Initiatives

11.10.           Abzena Ltd.

11.10.1.               Company Overview

11.10.2.               Product Offerings

11.10.3.               Financial Performance

11.10.4.               Recent Initiatives

Chapter 12.  Research Methodology

12.1.              Primary Research

12.2.              Secondary Research

12.3.              Assumptions

Chapter 13.  Appendix

13.1.              About Us

13.2.              Glossary of Terms

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/39181

Contact Us:

Vision Research Reports

Call: +1 9197 992 333

Email: sales@visionresearchreports.com

Leave a Reply

Your email address will not be published. Required fields are marked *